Biden Administration Proposes Major Shift in Cannabis Policy
The Biden administration has taken steps to reclassify marijuana use as a less serious crime. This potential policy change, if finalized, stands to be the most substantial adjustment in federal marijuana regulations in over four decades.
The U.S. Department of Justice, overseeing the Drug Enforcement Administration (DEA), has recommended reclassifying cannabis from a Schedule I drug, which denotes substances with a high potential for abuse and no accepted medical use, to a Schedule III drug. This reclassification would reflect a recognition of marijuana's lower potential for physical and psychological dependence compared to other controlled substances.
Shares of cannabis companies soared in response to the news, with stocks like Tilray, Trulieve Cannabis Corp, and Green Thumb Industries experiencing surges of over 20% in late afternoon trading. This market reaction underscores the significant financial implications of potential regulatory changes in the cannabis industry.
However, it's crucial to note that while the proposed reclassification may lessen the severity of penalties associated with marijuana use, it does not equate to outright legalization for recreational purposes. The shift in classification would likely result in revised sentencing guidelines and potentially open avenues for expanded medical research into cannabis-derived treatments.
The proposal is now in the hands of the White House Office of Management and Budget for review and the finalization of the rule-making process. Despite the positive reception from cannabis advocates and investors, the DEA has yet to officially comment on the recommendation.
The Biden administration's move reflects a growing shift in public attitudes towards marijuana, with an increasing number of states legalizing its recreational or medicinal use. By reevaluating federal cannabis policies, the administration aims to align with evolving societal norms and address longstanding disparities in drug enforcement practices.
Critics argue that the proposed reclassification does not go far enough in addressing broader issues related to drug policy reform, such as racial disparities in marijuana-related arrests and convictions. Nevertheless, proponents view it as a crucial step towards a more rational and equitable approach to cannabis regulation.
Technical Outlook
Canopy Growth Corporation (
CGC) stock is up 62% as a result of the Biden Administration policy on cannabis taking the stock to an overbought region with a Relative Strength Index (RSI) of 73.
Further accentuating to the bullish trend is the long "Bullish Harami" candle stick pattern depicted on the daily price chart.
The U.S. Department of Justice, overseeing the Drug Enforcement Administration (DEA), has recommended reclassifying cannabis from a Schedule I drug, which denotes substances with a high potential for abuse and no accepted medical use, to a Schedule III drug. This reclassification would reflect a recognition of marijuana's lower potential for physical and psychological dependence compared to other controlled substances.
Shares of cannabis companies soared in response to the news, with stocks like Tilray, Trulieve Cannabis Corp, and Green Thumb Industries experiencing surges of over 20% in late afternoon trading. This market reaction underscores the significant financial implications of potential regulatory changes in the cannabis industry.
However, it's crucial to note that while the proposed reclassification may lessen the severity of penalties associated with marijuana use, it does not equate to outright legalization for recreational purposes. The shift in classification would likely result in revised sentencing guidelines and potentially open avenues for expanded medical research into cannabis-derived treatments.
The proposal is now in the hands of the White House Office of Management and Budget for review and the finalization of the rule-making process. Despite the positive reception from cannabis advocates and investors, the DEA has yet to officially comment on the recommendation.
The Biden administration's move reflects a growing shift in public attitudes towards marijuana, with an increasing number of states legalizing its recreational or medicinal use. By reevaluating federal cannabis policies, the administration aims to align with evolving societal norms and address longstanding disparities in drug enforcement practices.
Critics argue that the proposed reclassification does not go far enough in addressing broader issues related to drug policy reform, such as racial disparities in marijuana-related arrests and convictions. Nevertheless, proponents view it as a crucial step towards a more rational and equitable approach to cannabis regulation.
Technical Outlook
Canopy Growth Corporation (
CGC) stock is up 62% as a result of the Biden Administration policy on cannabis taking the stock to an overbought region with a Relative Strength Index (RSI) of 73.Further accentuating to the bullish trend is the long "Bullish Harami" candle stick pattern depicted on the daily price chart.
⭐⭐⭐ Sign Up for Free ⭐⭐⭐
1) Download our Mobile App >> link-to.app/dexwirenews
2) Join our Telegram >> t.me/DEXWireNews
3) Sign Up for Text Alerts >>
dexwirenews.com/TEXT
4) Follow @DEXWireNews on Social Media
1) Download our Mobile App >> link-to.app/dexwirenews
2) Join our Telegram >> t.me/DEXWireNews
3) Sign Up for Text Alerts >>
dexwirenews.com/TEXT
4) Follow @DEXWireNews on Social Media
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.